MOUNTAIN VIEW, Calif.--(EON: Enhanced Online News)--Livongo Health, the leading consumer digital health company focused on empowering people with chronic conditions to live better and healthier lives, today announced a partnership with Glytec to offer eGlycemic Management System®, or eGMS®, to Livongo members. With this alliance, Livongo and Glytec will partner to deliver an expanded diabetes management solution that includes insulin titration, making managing diabetes easier for members and their providers.
“Glucommander Outpatient, A Cloud-Based Insulin Management Solution, Titrated Patients to Goal in 11 Days and Sustained a 2.6% Drop in HBA1C Over 6 Months.”
Managing medication can be complicated for people with diabetes and challenging for their providers. Studies have indicated that less than 50% of patients prescribed insulin achieve glycemic goals1 and 29% are non-adherent in taking their insulin2. Getting to the right insulin dosage requires ongoing monitoring and adjustment that isn’t always possible for providers to give efficiently or effectively.
Glucommander™, the application central to eGMS®, is already delivering substantive improvements in clinical outcomes, including insulin titration to goal in 11 days and sustained drops in A1C of 2.6%3. By creating an expanded solution, Livongo and Glytec aim to deliver improved health outcomes by integrating medication data, providing medication monitoring, and optimizing medication adherence.
“After more than a decade of accruing great results on the inpatient side with our therapy management software, and early successes in the outpatient realm, Glytec is excited to be furthering our reach through this partnership with such a pioneer and leader as Livongo,” says Dr. Andrew Rhinehart, Chief Medical Officer at Glytec. “The integrated, provider decision support solution that Glytec and Livongo together offer represents another exciting step forward in personalized and data-driven diabetes care. Livongo’s advanced approach to diabetes management, coupled with Glytec’s unique ability to support both basal and bolus insulin titration, provides the opportunity to truly disrupt the way the industry and providers address this critical aspect of diabetes care.”
“Partnering with FDA-cleared insulin algorithm companies allows us to connect more dots for our members and their providers,” said Dr. Jennifer Schneider, Chief Medical Officer at Livongo. “As a doctor and a person living with diabetes, I am excited about how this partnership will make it easier to stay healthy.”
In addition to delivering Livongo for Diabetes to people through the country’s leading self-insured employers, health plans, and health systems, Livongo is developing partnerships across the ecosystem to provide better tools and more information for our members and their physicians to improve care.
About Livongo Health
Livongo is the leading consumer digital health company that empowers people with chronic conditions to live better and healthier lives. We have developed a completely new approach for diabetes management that combines the latest technology with coaching. By offering the right information, tools, and support, at the right time, we provide our members with real-time, personalized insights and support to make diabetes management easier. Our approach is leading to better clinical and financial outcomes while also creating a better experience for people with diabetes and their care team of family, friends, and medical professionals. For more information visit: www.livongo.com. View and download Livongo’s latest images for media use at www.livongo.com/press.
For more information about Glytec, visit www.glytecsystems.com.
1 Bailey CJ, Kodack M. “Patient adherence to medication requirements for therapy of type 2 diabetes.” Int J Clin Pract. 2011 Mar; 65(3):314-22
2 Farsaei, Shadi et al.”Insulin adherence in patients with diabetes: Risk factors for injection omission.” Primary Care Diabetes, Volume 8, Issue 4, 338 - 345
3 Bode, Brude et al. “Glucommander Outpatient, A Cloud-Based Insulin Management Solution, Titrated Patients to Goal in 11 Days and Sustained a 2.6% Drop in HBA1C Over 6 Months.” Presentation at Advanced Technologies & Treatments for Diabetes 2017